Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other brokerages have also issued reports on MNPR. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. BTIG Research boosted their target price on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Zacks Research raised shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Finally, HC Wainwright upped their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Three analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Monopar Therapeutics currently has an average rating of “Buy” and an average price target of $112.08.

Monopar Therapeutics Stock Down 2.4%

Shares of Monopar Therapeutics stock opened at $116.35 on Friday. Monopar Therapeutics has a fifty-two week low of $29.18 and a fifty-two week high of $124.82. The firm has a market cap of $779.54 million, a PE ratio of -61.24 and a beta of 1.47. The business’s fifty day moving average is $91.87 and its two-hundred day moving average is $70.37.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. Equities research analysts anticipate that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in shares of Monopar Therapeutics in the first quarter worth $673,000. Jane Street Group LLC bought a new position in Monopar Therapeutics during the 1st quarter valued at $377,000. Geode Capital Management LLC boosted its stake in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after acquiring an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in Monopar Therapeutics during the 2nd quarter worth $209,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.